



Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

October 10, 2025

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Executive Officer, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Acquisition of Treasury Shares and the Purchase of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNeT-3), as well as the Cancellation of Treasury Shares

(The acquisition of treasury shares and the purchase of treasury shares through off-auction own share repurchase transaction [ToSTNeT-3] based on the Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act, and the cancellation of treasury shares pursuant to Article 178 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that, at the meeting of the Board of Directors held on October 10, 2025, the Company resolved to acquire treasury shares and determine the specific method of acquisition, based on the Articles of Incorporation pursuant to the provisions of Article 459, Paragraph 1 of the Companies Act, as well as to cancel treasury shares pursuant to Article 178 of the Companies Act, as outlined below.

1. Reason for acquisition of treasury shares

The Company will acquire treasury shares as part of its capital policy under the Medium-Term Management Plan, with the aim of enhancing shareholder returns and improving capital efficiency.

2. Method of acquisition of treasury shares

The Company will place an order through the Tokyo Stock Exchange’s off-auction own share repurchase transaction (ToSTNeT-3) at 8:45 a.m. on October 14, 2025, at ¥1,184, the closing price of the Company’s shares as of today (October 10, 2025), including the final special quote. No change will be made to other trading system or trading time. The buy order will be valid only during the aforementioned trading time.

3. Details of acquisition

- | | |
|--|--|
| (1) Class of shares to be acquired: | Common stock of the Company |
| (2) Total number of shares to be acquired: | Up to 250,000 shares
(Equivalent to 0.8% of the total number of shares issued, excluding treasury shares) |
| (3) Total acquisition cost of shares: | Up to ¥296,000,000 |
| (4) Disclosure of acquisition results: | The results of acquisition will be announced after the completion of the transaction at 8:45 a.m. on October 14, 2025. |

(Notes)

- 1 The number of shares to be acquired will not be changed. However, depending on market conditions and other factors, some or all of the acquisition may not be executed.
- 2 The purchase will be made against sell orders corresponding to the number of shares scheduled to be acquired.

4. Details of cancellation of treasury shares

- (1) Class of shares to be cancelled: Common stock of the Company
- (2) Total number of shares to be cancelled: 250,000 shares (scheduled)
(Equivalent to 0.8% of the total number of shares issued, excluding treasury shares)
- (3) Scheduled cancellation date: May 29, 2026

In addition, as announced today (October 10, 2025) in the “Notice Regarding the Acquisition of Treasury Shares and the Cancellation of Treasury Shares,” the Company has resolved, separately from the above, to acquire and cancel up to 1,000,000 shares of its treasury shares. As a result, the total number of shares to be acquired and cancelled will be up to 1,250,000 shares, representing 4.2% of the total number of shares issued (excluding treasury shares).

(Reference) Treasury shares held as of September 30, 2025

Total number of shares issued (excluding treasury shares): 30,080,366 shares

Number of treasury shares: 16,514 shares

Note: The above number of treasury shares does not include 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors.

End